1
|
Henriot P, El-Kassas M, Anwar W, Girgis SA, El Gaafary M, Jean K, Temime L. An agent-based model to simulate the transmission dynamics of bloodborne pathogens within hospitals. PLoS Comput Biol 2025; 21:e1012850. [PMID: 39993020 PMCID: PMC11882061 DOI: 10.1371/journal.pcbi.1012850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2024] [Revised: 03/05/2025] [Accepted: 02/05/2025] [Indexed: 02/26/2025] Open
Abstract
Mathematical models are powerful tools to analyze pathogen spread and assess control strategies in healthcare settings. Nevertheless, available models focus on nosocomial transmission through direct contact or aerosols rather than through blood, even though bloodborne pathogens remain a significant source of iatrogenic infectious risk. Herein, we propose an agent-based SEI (Susceptible-Exposed-Infected) model to reproduce the transmission of bloodborne pathogens dynamically within hospitals. This model simulates the dynamics of patients between hospital wards, from admission to discharge, as well as the dynamics of the devices used during at-risk invasive procedures, considering that patient contamination occurs after exposure to a contaminated device. We first illustrate the use of this model through a case study on hepatitis C virus (HCV) in Egypt. Model parameters, such as HCV upon-admission prevalence and transition probabilities between wards or ward-specific probabilities of undergoing different invasive procedures, are informed with data collected in Ain Shams University Hospital in Cairo. Our results suggest a low risk of HCV acquisition for patients hospitalized in this university hospital. However, we show that in a low-resource hospital, frequent device shortages could lead to increased risk. We also find that systematically screening patients in a few selected high-risk wards could significantly reduce this risk. We then further explore potential model applications through a second illustrative case study based on HBV nosocomial transmission in Ethiopia. In the future, this model could be used to predict the potential burden of emerging bloodborne pathogens and help implement effective control strategies in various hospital contexts.
Collapse
Affiliation(s)
- Paul Henriot
- Laboratoire Modélisation, Épidémiologie Et Surveillance Des Risques Sanitaires, Conservatoire national des arts et métiers (CNAM), Paris, France
- Unité PACRI, Risques Infectieux Et Émergents, CNAM-Institut Pasteur, Paris, France
- UMR EPIA, INRAE, Marcy-l’étoile, France
| | - Mohamed El-Kassas
- Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
| | - Wagida Anwar
- Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Samia A. Girgis
- Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Maha El Gaafary
- Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Kévin Jean
- Laboratoire Modélisation, Épidémiologie Et Surveillance Des Risques Sanitaires, Conservatoire national des arts et métiers (CNAM), Paris, France
- Unité PACRI, Risques Infectieux Et Émergents, CNAM-Institut Pasteur, Paris, France
- IBENS, Ecole normale supérieure, CNRS, INSERM, Université Paris Science & Lettres, Paris, France
| | - Laura Temime
- Laboratoire Modélisation, Épidémiologie Et Surveillance Des Risques Sanitaires, Conservatoire national des arts et métiers (CNAM), Paris, France
- Unité PACRI, Risques Infectieux Et Émergents, CNAM-Institut Pasteur, Paris, France
| |
Collapse
|
2
|
Shirreff G, Thiébaut ACM, Huynh BT, Chelius G, Fraboulet A, Guillemot D, Opatowski L, Temime L. Hospital population density and risk of respiratory infection: Is close contact density dependent? Epidemics 2024; 49:100807. [PMID: 39647461 DOI: 10.1016/j.epidem.2024.100807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2024] [Revised: 11/15/2024] [Accepted: 11/25/2024] [Indexed: 12/10/2024] Open
Abstract
Respiratory infections acquired in hospital depend on close contact, which may be affected by hospital population density. Models of infectious disease transmission typically assume that contact rates are independent of density (frequency dependence) or proportional to it (linear density dependence), without justification. We evaluate these assumptions by measuring contact rates in hospitals under different population densities. We analysed data from a study in 15 wards in which staff, patients and visitors carried wearable sensors which detected close contacts. We proposed a general model, non-linear density dependence, and fit this to data on several types of interactions. Finally, we projected the fitted models to predict the effect of increasing population density on epidemic risk. We identified considerable heterogeneity in density dependence between wards, even those with the same medical specialty. Interactions between all persons present usually depended little on the population density. However, increasing patient density was associated with higher rates of patient contact for staff and for other patients. Simulations suggested that a 10 % increase in patient population density would carry a markedly increased risk in many wards. This study highlights the variance in density dependent dynamics and the complexity of predicting contact rates.
Collapse
Affiliation(s)
- George Shirreff
- Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion, Paris, France; Université Paris-Saclay, UVSQ, Inserm, CESP, France; Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire National des Arts et Métiers, Paris, France.
| | | | - Bich-Tram Huynh
- Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion, Paris, France; Université Paris-Saclay, UVSQ, Inserm, CESP, France
| | | | | | - Didier Guillemot
- Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion, Paris, France; Université Paris-Saclay, UVSQ, Inserm, CESP, France; Department of Public Health, Medical Information, Clinical Research, AP-HP, Paris Saclay, Paris, France
| | - Lulla Opatowski
- Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion, Paris, France; Université Paris-Saclay, UVSQ, Inserm, CESP, France
| | - Laura Temime
- Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire National des Arts et Métiers, Paris, France; PACRI Unit, Institut Pasteur, Conservatoire national des Arts et Métiers, Paris, France
| |
Collapse
|
3
|
Grant R, Rubin M, Abbas M, Pittet D, Srinivasan A, Jernigan JA, Bell M, Samore M, Harbarth S, Slayton RB. Expanding the use of mathematical modeling in healthcare epidemiology and infection prevention and control. Infect Control Hosp Epidemiol 2024:1-6. [PMID: 39228083 DOI: 10.1017/ice.2024.97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/05/2024]
Abstract
During the coronavirus disease 2019 pandemic, mathematical modeling has been widely used to understand epidemiological burden, trends, and transmission dynamics, to facilitate policy decisions, and, to a lesser extent, to evaluate infection prevention and control (IPC) measures. This review highlights the added value of using conventional epidemiology and modeling approaches to address the complexity of healthcare-associated infections (HAI) and antimicrobial resistance. It demonstrates how epidemiological surveillance data and modeling can be used to infer transmission dynamics in healthcare settings and to forecast healthcare impact, how modeling can be used to improve the validity of interpretation of epidemiological surveillance data, how modeling can be used to estimate the impact of IPC interventions, and how modeling can be used to guide IPC and antimicrobial treatment and stewardship decision-making. There are several priority areas for expanding the use of modeling in healthcare epidemiology and IPC. Importantly, modeling should be viewed as complementary to conventional healthcare epidemiological approaches, and this requires collaboration and active coordination between IPC, healthcare epidemiology, and mathematical modeling groups.
Collapse
Affiliation(s)
- Rebecca Grant
- Infection Control Programme and WHO Collaborating Centre for Infection Prevention and Control and Antimicrobial Resistance, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Michael Rubin
- Division of Epidemiology, University of Utah School Medicine, Salt Lake City, UT, USA
| | - Mohamed Abbas
- Infection Control Programme and WHO Collaborating Centre for Infection Prevention and Control and Antimicrobial Resistance, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
- MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK
| | - Didier Pittet
- Infection Control Programme and WHO Collaborating Centre for Infection Prevention and Control and Antimicrobial Resistance, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Arjun Srinivasan
- Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - John A Jernigan
- Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Michael Bell
- Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Matthew Samore
- Division of Epidemiology, University of Utah School Medicine, Salt Lake City, UT, USA
| | - Stephan Harbarth
- Infection Control Programme and WHO Collaborating Centre for Infection Prevention and Control and Antimicrobial Resistance, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Rachel B Slayton
- Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|
4
|
Smith DRM, Duval A, Grant R, Abbas M, Harbarth S, Opatowski L, Temime L. Predicting consequences of COVID-19 control measure de-escalation on nosocomial transmission and mortality: a modelling study in a French rehabilitation hospital. J Hosp Infect 2024; 147:47-55. [PMID: 38467250 DOI: 10.1016/j.jhin.2024.02.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 02/13/2024] [Accepted: 02/21/2024] [Indexed: 03/13/2024]
Abstract
INTRODUCTION Infection control measures are effective for nosocomial COVID-19 prevention but bear substantial health-economic costs, motivating their "de-escalation" in settings at low risk of SARS-CoV-2 transmission. Yet consequences of de-escalation are difficult to predict, particularly in light of novel variants and heterogeneous population immunity. AIM To estimate how infection control measure de-escalation influences nosocomial COVID-19 risk. METHODS An individual-based transmission model was used to simulate SARS-CoV-2 outbreaks and control measure de-escalation in a French long-term care hospital with multi-modal control measures in place (testing and isolation, universal masking, single-occupant rooms). Estimates of COVID-19 case fatality rates (CFRs) from reported outbreaks were used to quantify excess COVID-19 mortality due to de-escalation. RESULTS In a population fully susceptible to infection, de-escalating both universal masking and single rooms resulted in hospital-wide outbreaks of 114 (95% CI: 103-125) excess infections, compared with five (three to seven) excess infections when de-escalating only universal masking or 15 (11-18) when de-escalating only single rooms. When de-escalating both measures and applying CFRs from the first wave of COVID-19, excess patient mortality ranged from 1.57 (1.41-1.71) to 9.66 (8.73-10.57) excess deaths/1000 patient-days. By contrast, when applying CFRs from subsequent pandemic waves and assuming susceptibility to infection among 40-60% of individuals, excess mortality ranged from 0 (0-0) to 0.92 (0.77-1.07) excess deaths/1000 patient-days. CONCLUSIONS The de-escalation of bundled COVID-19 control measures may facilitate widespread nosocomial SARS-CoV-2 transmission. However, excess mortality is probably limited in populations at least moderately immune to infection and given CFRs resembling those estimated during the 'post-vaccine' era.
Collapse
Affiliation(s)
- D R M Smith
- Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
| | - A Duval
- Epidemiology & Modelling of Antibiotic Evasion, Institut Pasteur, Université Paris-Cité, Paris, France; Anti-Infective Evasion & Pharmacoepidemiology, Université Paris-Saclay, UVSQ, INSERM, CESP, Montigny-Le-Bretonneux, France; Laboratoire MESuRS, Conservatoire National des Arts et Métiers, Paris, France
| | - R Grant
- Faculty of Medicine, University of Geneva, Geneva, Switzerland; Infection Control Programme & WHO Collaborating Centre on Infection Prevention and Control and Antimicrobial Resistance, Geneva University Hospitals, Geneva, Switzerland
| | - M Abbas
- Faculty of Medicine, University of Geneva, Geneva, Switzerland; Infection Control Programme & WHO Collaborating Centre on Infection Prevention and Control and Antimicrobial Resistance, Geneva University Hospitals, Geneva, Switzerland; MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK
| | - S Harbarth
- Faculty of Medicine, University of Geneva, Geneva, Switzerland; Infection Control Programme & WHO Collaborating Centre on Infection Prevention and Control and Antimicrobial Resistance, Geneva University Hospitals, Geneva, Switzerland
| | - L Opatowski
- Epidemiology & Modelling of Antibiotic Evasion, Institut Pasteur, Université Paris-Cité, Paris, France; Anti-Infective Evasion & Pharmacoepidemiology, Université Paris-Saclay, UVSQ, INSERM, CESP, Montigny-Le-Bretonneux, France
| | - L Temime
- Laboratoire MESuRS, Conservatoire National des Arts et Métiers, Paris, France
| |
Collapse
|
5
|
Zitzmann C, Ke R, Ribeiro RM, Perelson AS. How robust are estimates of key parameters in standard viral dynamic models? PLoS Comput Biol 2024; 20:e1011437. [PMID: 38626190 PMCID: PMC11051641 DOI: 10.1371/journal.pcbi.1011437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 04/26/2024] [Accepted: 04/01/2024] [Indexed: 04/18/2024] Open
Abstract
Mathematical models of viral infection have been developed, fitted to data, and provide insight into disease pathogenesis for multiple agents that cause chronic infection, including HIV, hepatitis C, and B virus. However, for agents that cause acute infections or during the acute stage of agents that cause chronic infections, viral load data are often collected after symptoms develop, usually around or after the peak viral load. Consequently, we frequently lack data in the initial phase of viral growth, i.e., when pre-symptomatic transmission events occur. Missing data may make estimating the time of infection, the infectious period, and parameters in viral dynamic models, such as the cell infection rate, difficult. However, having extra information, such as the average time to peak viral load, may improve the robustness of the estimation. Here, we evaluated the robustness of estimates of key model parameters when viral load data prior to the viral load peak is missing, when we know the values of some parameters and/or the time from infection to peak viral load. Although estimates of the time of infection are sensitive to the quality and amount of available data, particularly pre-peak, other parameters important in understanding disease pathogenesis, such as the loss rate of infected cells, are less sensitive. Viral infectivity and the viral production rate are key parameters affecting the robustness of data fits. Fixing their values to literature values can help estimate the remaining model parameters when pre-peak data is missing or limited. We find a lack of data in the pre-peak growth phase underestimates the time to peak viral load by several days, leading to a shorter predicted growth phase. On the other hand, knowing the time of infection (e.g., from epidemiological data) and fixing it results in good estimates of dynamical parameters even in the absence of early data. While we provide ways to approximate model parameters in the absence of early viral load data, our results also suggest that these data, when available, are needed to estimate model parameters more precisely.
Collapse
Affiliation(s)
- Carolin Zitzmann
- Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico
| | - Ruian Ke
- Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico
| | - Ruy M. Ribeiro
- Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico
| | - Alan S. Perelson
- Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico
| |
Collapse
|
6
|
Potestio L, Megna M, Villani A, Cacciapuoti S, Scalvenzi M, Martora F. Herpes Zoster and COVID-19 Vaccination: A Narrative Review. Clin Cosmet Investig Dermatol 2023; 16:3323-3331. [PMID: 38021418 PMCID: PMC10658959 DOI: 10.2147/ccid.s441898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 11/13/2023] [Indexed: 12/01/2023]
Abstract
COVID-19 was a worldwide emergency, leading to a global health crisis, which completely revolutionized every aspect of human life. Several strategies were adopted to limit the spreading of the infection such as testing and contact tracing, quarantine and isolation, use of face mask, social distancing, lockdowns, travel restrictions, etc. Of these, vaccines were the most important measures to reduce the transmission of the virus and the severity of the infection, in order to overcome the pandemic. Fortunately, vaccination campaign was a success, showing to be efficient in controlling and preventing the COVID-19, reducing the risk of disease progression, hospitalization, and mortality. Monitoring and addressing vaccine-related adverse events have been essential for maintaining public confidence. Indeed, with the increasing number of vaccines administered, various cutaneous reactions have been reported, making dermatologists key players in their recognition and treatment. Particularly, several cutaneous diseases and cutaneous findings have been reported. Of note, also viral reactivations have been described following COVID-19 vaccination. Among these, varicella zoster virus (VZV) reactivation has been collected. Globally, an early diagnosis and an accurate treatment of herpes zoster (HZ) is mandatory to reduce possible complications. In this context, we conducted a review of the current literature investigating cases HZ following COVID-19 vaccination with the aim of understanding the possible causal correlation and underlying pathogenetic mechanisms to offer clinicians a wide perspective on VZV reactivation and COVID-19 vaccines.
Collapse
Affiliation(s)
- Luca Potestio
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Matteo Megna
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Alessia Villani
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Sara Cacciapuoti
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Massimiliano Scalvenzi
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Fabrizio Martora
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| |
Collapse
|